Abstracts tagged "Gene Expression"

Abstract Number: 2865 • 2013 ACR/ARHP Annual Meeting
Gene Expression Profiles Of Fibroblast-Like Synoviocytes In Early Stage Of Oligoarticular Juvenile Idiopathic Arthritis Are Different In Extended Versus Persistent Course
AnneMarie C. Brescia¹, Megan M. Simonds², Suzanne M. McCahan², Paul T. Fawcett² and Carlos D. Rose¹, ¹Pediatric Rheumatology, Thomas Jefferson University/ AI duPont Hospital for Children, Wilmington, DE, ²Nemours Research, Nemours/AI duPont Hospital for Children, Wilmington, DE
Background/Purpose: Our goal is the identification of informative synovial biomarkers to predict persistent vs extended course in oligoarticular JIA patients. Methods: Stored remnant synovial fluid…
Abstract Number: 1565 • 2013 ACR/ARHP Annual Meeting
RNA-Sequencing Confirms Clinical Safety Of Herpes Zoster Vaccine
Christopher J. Lessard^1,2, Indra Adrianto³, Joel M. Guthridge⁴, John A. Ice³, Graham B. Wiley³, Stuart B. Glenn³, Judith A. James^1,2, Joan T. Merrill¹, Patrick M. Gaffney¹, Courtney G. Montgomery³, Kathy L. Sivils^1,5 and Eliza Chakravarty³, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: SLE patients have increased risk of Herpes Zoster (HZ). A live-attenuated vaccine is available for healthy persons > 50 years old, but its safety…
Abstract Number: 32 • 2013 ACR/ARHP Annual Meeting
Understanding The Stimulatory Pathways Responsible For Naïve B Cell Activation In Systemic Lupus Erythematosus
Emily Blalock¹, Chris Scharer², Scott Jenks¹, Jeremy Boss² and Ignacio Sanz³, ¹Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, ³Allergy, Immunology and Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is a recurrent autoimmune disease characterized by multiple B cell abnormalities, including the activation of naïve B cells. However, gaps…
Abstract Number: 2874 • 2013 ACR/ARHP Annual Meeting
Biological Roles of C5orf30 In Rheumatoid Arthritis Synovial Fibroblasts
Munitta Muthana¹, Holly Davies², Sachin Khetan³, Gbadebo Adeleke Adeleke⁴, Sarah Hawtree¹ and Anthony G. Wilson⁵, ¹Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, ²University of Sheffield, Sheffield, United Kingdom, ³Infection and immunity, Dr, Sheffield, United Kingdom, ⁴Infection and Immunity, Dr, Sheffield, United Kingdom, ⁵Infection & Immunity, University of Sheffield, Sheffield, United Kingdom
Background/Purpose: A recent genome wide association study identified the variant rs26232 in the first intron of an uncharacterized gene C5orf30 as a rheumatoid arthritis susceptibility…
Abstract Number: 1488 • 2013 ACR/ARHP Annual Meeting
Gene Expression Profile According To Systemic Disease Activity In Primary Sjögren’s Syndrome: Results From The Assessment Of Systemic Signs and Evolution Of Primary Sjögren’s Syndrome (ASSESS) Cohort
Nawal Rahal¹, Nicolas Cagnard², Ghada Alsaleh³, Raphaèle Seror⁴, Corinne Miceli-Richard⁵, Joelle Benessiano⁶, Philippe Dieude⁷, Jean Jacques Dubost⁸, Anne-Laure Fauchais⁹, Vincent Goeb¹⁰, Eric Hachulla¹¹, Pierre-Yves Hatron¹², C. Larroche¹³, Véronique le Guern¹⁴, Jacques Morel¹⁵, Aleth Perdriger¹⁶, Xavier Puechal¹⁷, Stephanie Rist¹⁸, Alain Saraux¹⁹, Damien Sene²⁰, Jean Sibilia²¹, Olivier Vittecoq²², Philippe Ravaud²³, Xavier Mariette²⁴ and Jacques-Eric Gottenberg²¹, ¹Strasbourg University Hospital, STRASBOURG, France, ²Institut Cochin, 75014 Paris, France, ³Univerity of Strasbourg, STRASBOURG, France, ⁴Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, ⁵Rheumatology Department, Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre, France, ⁶Rheumatology, Paris Unervisity Hospital BICHAT, Paris, France, ⁷Rheumatology, Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France, ⁸Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ⁹Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, ¹⁰Rheumatology, Amiens University Hospital, Amiens, France, ¹¹Internal Medicine, Lille CEDEX, France, ¹²Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹³Hospital University Bobigny, bobigny, France, ¹⁴Department of Internal Medicine, Hôpital Cochin, Paris, France, ¹⁵Montpellier University Hospital, Montpellier, France, ¹⁶Rheumatology, Hôpital Sud, Rennes, France, ¹⁷Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹⁸Rheumatology, Orleans Hospital, Orleans, France, ¹⁹Rhumatologie, CHU de la Cavale Blanche, Brest Cedex, France, ²⁰Internal Medicine, Hopital Lariboisière, Paris, France, ²¹Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ²²Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, ²³Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ²⁴Paris-Sud University, Paris, France
Background/Purpose: In primary Sjögren’s syndrome (pSS), the pathogenesis of systemic complications remains unclear. Only few gene expression studies were performed and concerned a limited number…
Abstract Number: 2772 • 2013 ACR/ARHP Annual Meeting
Identification Of a Sjögren’s Syndrome-Associated Variant That Influences OAS1 Isoform Switching
He Li^1,2, John A. Ice³, Jennifer A. Kelly³, Indra Adrianto¹, Stuart B. Glenn³, Kimberly S. Hefner⁴, Evan G. Vista⁵, Donald U. Stone⁶, Raj Gopalakrishnan⁷, Glen D. Houston⁸, David M. Lewis⁹, Michael Rohrer⁷, Pamela Hughes⁷, John B. Harley^10,11, Courtney G. Montgomery³, James Chodosh¹², James A. Lessard¹³, Juan-Manuel Anaya¹⁴, Barbara M. Segal¹⁵, Nelson L. Rhodus¹⁶, Lida Radfar², R. Hal Scofield¹⁷, Christopher J. Lessard^3,18 and Kathy L. Sivils¹, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁵Rheumatology and Clinical Immunology, University of Santo Tomas, Taguig City, Philippines, ⁶Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ⁸Collage of Denistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹¹US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹²Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ¹³Valley Bone and Joint Clinic, Grand Forks, ND, ¹⁴Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, ¹⁵Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹⁶University of Minnesota, Minneapolis, MN, ¹⁷Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a common, progressive autoimmune exocrinopathy characterized by symptoms of dry eyes and mouth present in 0.7-1% of the European population.…
Abstract Number: 1489 • 2013 ACR/ARHP Annual Meeting
RNA-Sequencing Identifies Novel Differentially Expressed Coding and Non-Coding Transcripts In Sjögren’s Syndrome
Indra Adrianto¹, Mikhail G. Dozmorov², Graham B. Wiley¹, John A. Ice¹, He Li^1,3, Jennifer A. Kelly¹, Astrid Rasmussen¹, Donald U. Stone⁴, Juan-Manuel Anaya⁵, Barbara M. Segal⁶, Nelson L. Rhodus⁷, Lida Radfar⁸, John B. Harley^9,10, Judith A. James¹¹, Courtney G. Montgomery¹, R. Hal Scofield^12,13,14, Patrick M. Gaffney¹, Jonathan D. Wren¹, Kathy L. Sivils^1,3 and Christopher J. Lessard^1,3, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clincial Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, ⁶Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ⁷University of Minnesota, Minneapolis, MN, ⁸University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹¹Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ¹³College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a common, clinically heterogeneous autoimmune disease characterized by exocrine gland dysfunction that involves both innate and adaptive immune responses. SS…
Abstract Number: 2559 • 2013 ACR/ARHP Annual Meeting
Effect Of NOX4 Overexpression On The Levels Of Micro RNAs Relevant To Systemic Sclerosis Fibrotic Process
Sonsoles Piera-Velazquez, Alma Makul and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Systemic sclerosis (SSc) is characterized by the excessive deposition of collagen and other connective tissue components in skin and multiple internal organs. Although transforming…
Abstract Number: 1398 • 2013 ACR/ARHP Annual Meeting
Comparison Of Atherogenicity Of Plasma From Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Beenish Hafiz¹, Iryna Voloshyna², Michael J. Littlefield², Steven E. Carsons³, Elise Belilos¹, Kristina Belostocki¹, Lois A. Bonetti⁴, Gary C. Rosenblum¹ and Allison B. Reiss², ¹Rheumatology, Winthrop University Hospital, Mineola, NY, ²Medicine, Winthrop University Hospital, Mineola, NY, ³Div of Rheumatology, Winthrop University Hospital, Mineola, NY, ⁴Rheum & Immun, Winthrop University Hospital, Mineola, NY
Background/Purpose: Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are immune mediated inflammatory disorders linked to increased risk of cardiovascular disease (CVD), mostly due to accelerated…
Abstract Number: 2560 • 2013 ACR/ARHP Annual Meeting
Analysis Of Global Gene Expression Of Pulmonary Endothelial Cells From Caveolin-1 Knock-Out Mice
Sonsoles Piera-Velazquez¹, Zhaodong Li¹, Sankar Addya², Peter J. Wermuth¹ and Sergio A. Jimenez¹, ¹Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA, ²Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Caveolin-1 (Cav-1) deficiency has recently been shown to participate in the pathogenesis of tissue fibrosis in Systemic Sclerosis (SSc). Although the mechanisms involved have…
Abstract Number: 1284 • 2013 ACR/ARHP Annual Meeting
Nuclear Receptor 4A2 Is Differentially Expressed In Animal Models Of RA During Inflammation and Resolution
Jordan Everett¹, Fiona E. McCann², Andrew C. Palfreeman², Anita T. Shaw³, Ellen M. Gravallese⁴ and Kimberlee S. Mix¹, ¹Biological Sciences, Loyola University New Orleans, New Orleans, LA, ²NDORMS, The Kennedy Institute of Rheumatology, University of Oxford, London, United Kingdom, ³Division of Rheumatology, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ⁴Department of Medicine, Division of Rheumatology, UMass Memorial Medical Center, Worcester, MA
Background/Purpose: Nuclear receptor 4A2 (NR4A2 / nuclear receptor related 1 / Nurr1) is a constitutively active transcription factor with diverse roles in normal physiology and…
Abstract Number: 2566 • 2013 ACR/ARHP Annual Meeting
Nilotinib Treatment Effect In The Skin As Measured By DNA Microarray In Patients With Diffuse Systemic Sclerosis
Jessica K. Gordon¹, Tammara A. Wood², Robert F. Spiera¹ and Michael L. Whitfield², ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Gene expression profiling by DNA microarray is used to identify potential biomarkers in Systemic Sclerosis (SSc). Discrete gene expression signatures have been observed to…
Abstract Number: 1175 • 2013 ACR/ARHP Annual Meeting
ABCG2 May Influence Risk Of Gout Through Extra-Renal Metabolic Pathways: Analysis Of The Effects Of The Q141K Variant On Serum Urate Responses To a Fructose Load
Nicola Dalbeth¹, Meaghan House², Gregory Gamble², Bregina Pool¹, Anne Horne², Lauren Purvis², Angela Stewart², Marilyn E. Merriman³, Murray Cadzow⁴, Amanda Phipps-Green³ and Tony R. Merriman³, ¹Medicine, University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Department of Biochemistry, University of Otago, Dunedin, New Zealand, ⁴University of Otago, Dunedin, New Zealand
Background/Purpose: Genetic variation in ABCG2 is a major risk factor for hyperuricemia and gout. This gene encodes a high-capacity urate transporter expressed in the intestine,…
Abstract Number: 2501 • 2013 ACR/ARHP Annual Meeting
Validation Of Gene Expression Biomarkers Of Psoriatic Arthritis
Fatima Abji¹, Remy Pollock¹, Fawnda Pellett², Kun Liang³, Vinod Chandran² and Dafna D. Gladman², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a seronegative immune mediated arthritis that develops in about a third of patients with cutaneous psoriasis (PsC). The cellular pathways…
Abstract Number: 1171 • 2013 ACR/ARHP Annual Meeting
Treatment Of Psoriasis Patients With IMO-3100 Shows Improvement In Gene Expression Patterns Of Meta-Analysis Derived-3 Transcriptome and IL-17 Pathway
Mayte Suarez-Farinas¹, Jennifer Belasco¹, Tim Sullivan², Robert Arbeit² and James G. Krueger¹, ¹Krueger Laboratory, The Rockefeller University, New York, NY, ²Idera Pharmaceuticals, Inc., Cambridge, MA

Background/Purpose: IMO‑3100, an antagonist of TLRs 7 and 9, has shown significant improvement in Psoriasis Area and Severity Index (PASI) scores in a randomized, double‑blind,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.